Literature DB >> 25232226

Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases.

Wei Wang1, Sharvesh Raj Seeruttun1, Cheng Fang1, Zhiwei Zhou1.   

Abstract

A 64-year-old man was admitted to the Sun Yat-Sen University Cancer Center with chief complaints of recurrent abdominal pain and diarrhea for about 3 years and with a history of surgical repair for intestinal perforation owing to stress ulcer. Positron emission tomography (PET)/computed tomography (CT) demonstrated a primary tumor on the pancreatic tail with multifocal liver metastases. Pathological and immunohistochemistry staining revealed the lesion to be a pancreatic neuroendocrine tumor (pNET). According to the latest World Health Organization (WHO, 2013) classification, the tumor was classified as stage IV functional G1 pNET. After referral to the multidisciplinary treatment board (MDT), the patient was started on periodic dose of omeprazole, somatostatin analogues and Interferon α (IFNα) and had scanning follow-ups. Based upon the imaging results, CT-guided radioactive iodine-125 ((125)I) seeds implantation therapy, radiofrequency ablation therapy (RFA) or microwave ablation technique were chosen for the treatment of the primary tumor. Transarterial chemoembolization (TACE), RFA and microwave ablation techniques were decided upon for liver metastases. The patient showed beneficial response to the treatment with clinically manageable low-grade side effects and attained partial remission (RECIST criteria) with a good quality of life.

Entities:  

Keywords:  Pancreatic neuroendocrine tumor (pNET); functional; liver metastases; multidisciplinary team; prognosis

Year:  2014        PMID: 25232226      PMCID: PMC4153935          DOI: 10.3978/j.issn.1000-9604.2014.08.16

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  17 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

3.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 5.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 7.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

Authors:  Thomas J Vogl; Nagy N N Naguib; Stefan Zangos; Katrin Eichler; Alborz Hedayati; Nour-Eldin A Nour-Eldin
Journal:  Eur J Radiol       Date:  2008-10-01       Impact factor: 3.528

8.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

9.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

10.  Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.

Authors:  C Lombard-Bohas; E Mitry; D O'Toole; C Louvet; D Pillon; G Cadiot; F Borson-Chazot; T Aparicio; M Ducreux; T Lecomte; P L Etienne; W Cacheux; J L Legoux; J F Seitz; P Ruszniewski; J A Chayvialle; P Rougier
Journal:  Neuroendocrinology       Date:  2008-08-22       Impact factor: 4.914

View more
  1 in total

Review 1.  Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role?

Authors:  Sergio Sartori; Lara Bianchi; Francesca Di Vece; Paola Tombesi
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.